Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748134 · ClinicalTrials.gov registry record · Phase 3
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
A Phase 3 study of Esophageal Squamous Cell Carcinoma, sponsored by Innovent Biologics (Suzhou) Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 746
- Enrollment target
- 20
- Study locations
NCT03748134 is a Phase 3 study of Esophageal Squamous Cell Carcinoma that has completed, run by Innovent Biologics (Suzhou) Co.. The registered enrollment target is 746 participants, above the 347-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (115% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT03748134, a Phase 3 study of Esophageal Squamous Cell Carcinoma, has completed, sponsored by Innovent Biologics (Suzhou) Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 746 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma. After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilimab in combination with chemotherapy in subjects representing the western population with advanced esophageal squamous cell carcinoma
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cisplatin
- DRUG Fluorouracil
- DRUG Paclitaxel
- BIOLOGICAL Sintilimab
Study Locations (20)
Other
- Institut Jules Bordet - Brussels
- Centre Hospitalier Regional de Verviers - Verviers
- Beijing Cancer Hospital - Beijing
- Hôpital Jean Minjoz - Bettancourt-la-Ferrée
- Institut Bergonié - Bordeaux
California
- St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center - Anaheim
- UC Irvine - Orange
Western Australia
- Sir Charles Gairdner Hospital - Nedlands
- St John of God Subiaco Hospital - Subiaco
Colorado
- Rocky Mountain Cancer Centers, LLP - Denver
Georgia
- IACT Health - John B. Amos Cancer center - Columbus
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Texas
- Texas Oncology, P.A. - Austin
Washington
- Northwest Cancer Specialists, P.C. - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 746 participants |
| Start Date | 2018-12-24 |
| Est. Completion | 2023-07-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03748134
The ClinicalTrials.gov registry entry for NCT03748134 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 746 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 347-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (115% higher). The listed sponsor is Innovent Biologics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT03748134 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Western Australia.
Frequently Asked Questions
What is clinical trial NCT03748134 about?
NCT03748134 is a clinical study titled "Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )". This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma. After the ...
What is the current status of trial NCT03748134?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 746 participants. The study started on 2018-12-24. Estimated completion is 2023-07-29.
What conditions does trial NCT03748134 study?
This clinical trial studies the following conditions: Esophageal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT03748134?
The interventions under investigation include: Placebo (DRUG), Cisplatin (DRUG), Fluorouracil (DRUG), Paclitaxel (DRUG), Sintilimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03748134?
This trial is sponsored by Innovent Biologics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03748134 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
RECRUITING · Phase 3
-
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
ACTIVE NOT RECRUITING · Phase 3
-
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.